SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-051552
Filing Date
2021-02-23
Accepted
2021-02-23 08:05:54
Documents
14
Period of Report
2021-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d125056d8k.htm   iXBRL 8-K 25220
2 EX-99.1 d125056dex991.htm EX-99.1 87508
6 GRAPHIC g125056g0223074009827.jpg GRAPHIC 4588
  Complete submission text file 0001193125-21-051552.txt   257363

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvs-20210223.xsd EX-101.SCH 3088
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20210223_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20210223_pre.xml EX-101.PRE 11420
7 EXTRACTED XBRL INSTANCE DOCUMENT d125056d8k_htm.xml XML 3361
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 21663161
SIC: 2834 Pharmaceutical Preparations